Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Olfactomedin-like protein 1 (OLFML1) is a secreted glycoprotein of the olfactomedin family, encoded by the OLFML1 gene located on human chromosome 11p15.4[1][4]. It contains an olfactomedin domain and consists of 402 amino acids[1][4]. OLFML1 is highly expressed in non-neural tissues such as small intestine, liver, lung, heart, and spleen, and has minimal to no expression in the brain[1][4]. Its protein enhances human cancer cell proliferation *in vitro* through acceleration of the cell cycle S phase entry[1], and it is involved in osteoblast biology—specifically, it inhibits Hippo signaling and affects mineralization, thus contributing to bone development and potentially to diseases like congenital scoliosis via effects on osteoblast differentiation[3]. Although OLFML1 belongs to a protein family implicated in several pathological processes, its explicit physiological and pathological roles, as well as its therapeutic targeting potential, require further research[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Olfactomedin-like protein 1 (OLFML1).